VERIGRAFT Advances into Pivotal Trial for Regenerative CVI Therapy

VERIGRAFT Advances into Pivotal Trial for Regenerative CVI Therapy

By, Admin 26 March 2026

A small biotech is making a big bet on curative vascular medicine. VERIGRAFT has initiated a pivotal Phase II/III trial of its lead therapy, P-TEV (personalized tissue-engineered vein), targeting Chronic Venous Insufficiency (CVI). The goal: US and European approval by 2028.

Why This Matters?

CVI is:

  • Progressive
  • Underdiagnosed
  • Poorly treated at advanced stages

Patients suffer from:

  • Chronic leg swelling
  • Pain and skin damage
  • Venous ulcers in severe cases

Current treatments manage symptoms. They do not fix the underlying problem.

What Makes P-TEV Different

P-TEV is not a drug. It is a personalized, biological implant.

How It Works

  • Uses donor-derived vein material
  • Removes cellular components (decellularization)
  • Re-engineers it using the patient’s own blood
  • Creates a patient-specific graft with functional valves

The graft is then surgically implanted to:

  • Replace damaged veins
  • Restore natural blood flow

Key Advantage: No Immunosuppression

Most transplant-based therapies require immune suppression. P-TEV avoids that. Because it is biologically personalized:

  • Lower risk of rejection
  • No long-term immunosuppressive drugs
  • More natural integration into the body

This is a major differentiator.

Speed and Scalability

One of the biggest barriers in regenerative medicine is manufacturing.

VERIGRAFT claims:

  • 10-day production timeline
  • Scalable process
  • Protected by 92 granted patents

That combination—speed + IP—matters if this reaches commercialization.

Trial Design: Pivotal Phase II/III

The study is designed to generate registrational data.

Key Details

  • Trial sites: Spain, Netherlands, Poland
  • Product type: Advanced Therapy Medicinal Product (ATMP)
  • Target: Patients with advanced CVI

Unlike traditional large trials, ATMP pathways allow:

  • Smaller patient populations
  • High-quality, targeted clinical data

Market Opportunity

The CVI market is not small.

  • Projected to reach $5.9 billion by 2034

Drivers include:

  • Aging populations
  • Rising obesity
  • Sedentary lifestyles

Despite that, no curative treatment exists today.

Funding and Backing

VERIGRAFT secured:

  • $10 million in financing from existing investors

This funding supports:

  • Trial execution
  • Clinical development progression

Clinical Perspective

Experts involved in the trial highlight a fundamental shift.  Bryan Kluck noted that:

  • The therapy could restore normal venous function
  • It represents a restorative approach, not symptomatic care

Andrés García León added:

  • Current options for advanced CVI are limited
  • P-TEV could offer a scalable physiological solution

Leadership View

Petter Björquist positioned this as a defining step:

  • Moving from concept to clinical reality
  • Targeting the root cause of disease
  • Building a platform for scalable regenerative therapy

The Bigger Picture

This sits at the intersection of three major trends:

  • Personalized medicine
  • Regenerative therapies
  • Biologic implants

If successful, P-TEV could:

  • Redefine how vascular disease is treated
  • Shift care from management to restoration
  • Open the door for similar tissue-engineered solutions

Final Takeaway

This is high-risk, high-reward. -TEV is attempting something most therapies avoid: Fix the biology, not just manage the symptoms. If the Phase II/III trial delivers, this will not just be a new product. It will be a new treatment paradigm for chronic venous disease.

Optimize Your trial insights with Clival Database.

Are you exhausted from the uncertainty of trial insights pricing? Clival Database ensures the clarity in the midst of the global scenario for clinical trials to you.

Clival Database is one of the best databases that offers an outstanding number of clinical trial data in terms of 50,000+ molecules and from primary regulatory markets as well as new entrants like Indian and Chinese markets.

With Clival, you get accurate positioning of historical sales data, patent database, company profiling, safety & efficacy, and prediction of launch of new innovative molecules helping you to align your research and driving down the cost.

To add value, we further break down our analytics for you so that improving your operational effectiveness; optimizing your clinical trials; and offering you accurate and high-quality data at lowest possible prices becomes possible.

Elevate your trial success rate with the cutting-edge insights from Clival database.

Check it out today and make more informed sourcing decisions! Learn More!